168 related articles for article (PubMed ID: 20018308)
1. Does neoadjuvant hormonal therapy improve urinary function when given to men with large prostates undergoing prostate brachytherapy?
Stone NN; Marshall DT; Stone JJ; Cesaretti JA; Stock RG
J Urol; 2010 Feb; 183(2):634-9. PubMed ID: 20018308
[TBL] [Abstract][Full Text] [Related]
2. Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy.
Mabjeesh NJ; Chen J; Stenger A; Matzkin H
Urology; 2007 Sep; 70(3):548-53. PubMed ID: 17905113
[TBL] [Abstract][Full Text] [Related]
3. The effect of brachytherapy, external beam irradiation and hormonal therapy on prostate volume.
Stone NN; Stock RG
J Urol; 2007 Mar; 177(3):925-8. PubMed ID: 17296377
[TBL] [Abstract][Full Text] [Related]
4. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy.
Hinerman-Mulroy A; Merrick GS; Butler WM; Wallner KE; Allen Z; Adamovich E
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1367-82. PubMed ID: 15275722
[TBL] [Abstract][Full Text] [Related]
5. Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy.
Kollmeier MA; Stock RG; Cesaretti J; Stone NN
J Urol; 2005 Mar; 173(3):808-12. PubMed ID: 15711274
[TBL] [Abstract][Full Text] [Related]
6. The effect of hormonal manipulation on urinary function following permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Murray B; Allen Z; Lief JH; Galbreath RW
Brachytherapy; 2004; 3(1):22-9. PubMed ID: 15110310
[TBL] [Abstract][Full Text] [Related]
7. Seed implant retention score predicts the risk of prolonged urinary retention after prostate brachytherapy.
Lee HK; Adams MT; Shi Q; Basillote J; Lamonica J; Miranda L; Motta J
Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1445-9. PubMed ID: 19553032
[TBL] [Abstract][Full Text] [Related]
8. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
[TBL] [Abstract][Full Text] [Related]
9. Dynamic dose-feedback prostate brachytherapy in patients with large prostates and/or planned transurethral surgery before implantation.
Acher PL; Popert R; Morris SL; Potters L; Austin-Smith SL; Johnson UH; Nichol JE; Beaney RP
BJU Int; 2007 May; 99(5):1066-71. PubMed ID: 17233801
[TBL] [Abstract][Full Text] [Related]
10. Predictive factors of acute urinary retention requiring catheterization following 125I prostate brachytherapy.
Ohashi T; Yorozu A; Toya K; Saito S; Momma T
Jpn J Clin Oncol; 2006 May; 36(5):285-9. PubMed ID: 16698803
[TBL] [Abstract][Full Text] [Related]
11. Editorial comment.
Pinkawa M
J Urol; 2010 Feb; 183(2):639; discussion 639-40. PubMed ID: 20018310
[No Abstract] [Full Text] [Related]
12. Editorial comment.
Williams SG
J Urol; 2010 Feb; 183(2):639; discussion 639-40. PubMed ID: 20018309
[No Abstract] [Full Text] [Related]
13. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
Crook J; Ludgate C; Malone S; Lim J; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):15-23. PubMed ID: 15337535
[TBL] [Abstract][Full Text] [Related]
14. Patterns of local failure following prostate brachytherapy.
Stone NN; Stock RG; White I; Unger P
J Urol; 2007 May; 177(5):1759-63; duscussion 1763-4. PubMed ID: 17437808
[TBL] [Abstract][Full Text] [Related]
15. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
[TBL] [Abstract][Full Text] [Related]
16. Long-term urinary sequelae following 125iodine prostate brachytherapy.
Crook J; Fleshner N; Roberts C; Pond G
J Urol; 2008 Jan; 179(1):141-5; discussion 146. PubMed ID: 17997424
[TBL] [Abstract][Full Text] [Related]
17. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
18. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
Vargas C; MartÃnez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
[TBL] [Abstract][Full Text] [Related]
19. Failure to achieve a PSA level Mitchell DM; McAleese J; Park RM; Stewart DP; Stranex S; Eakin RL; Houston RF; O'Sullivan JM
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1467-71. PubMed ID: 17689886
[TBL] [Abstract][Full Text] [Related]
20. Mortality in men with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormone therapy.
Dosoretz AM; Chen MH; Salenius SA; Ross RH; Dosoretz DE; Katin MJ; Mantz C; Nakfoor BM; D'Amico AV
Cancer; 2010 Feb; 116(4):837-42. PubMed ID: 20052734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
